Insider Selling: Becton, Dickinson and Company (NYSE:BDX) EVP Sells 75 Shares of Stock

Becton, Dickinson and Company (NYSE:BDX) EVP Michael Feld sold 75 shares at $193.36 each, totaling $14,502. Post-sale, he owns 16,580 shares valued at $3,205,908.80, a 0.45% decrease in ownership. The transaction was disclosed in an SEC filing. Feld also sold shares on October 27th and September 26th. BDX stock traded at $190.51, with a market cap of $54.38 billion. The company reported $4.10 EPS for the last quarter and increased its quarterly dividend to $1.05. Institutional investors hold 86.97% of BDX shares.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) EVP Michael Feld sold 75 shares of the company's stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $193.36, for a total transaction of $14,502.00. Following the completion of the sale, the executive vice president directly owned 16,580 shares in the company, valued at approximately $3,205,908.80. The trade was a 0.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

Intuitive Surgical Gives Buying Opportunity Off Its 52 Week Highs

Michael Feld also recently made the following trade(s):

On Monday, October 27th, Michael Feld sold 57 shares of Becton, Dickinson and Company stock. The stock was sold at an average price of $186.01, for a total value of $10,602.57.
On Friday, September 26th, Michael Feld sold 58 shares of Becton, Dickinson and Company stock. The stock was sold at an average price of $181.03, for a total value of $10,499.74.

Becton, Dickinson and Company Stock Performance

NYSE:BDX traded down $1.31 on Tuesday, hitting $190.51. The company's stock had a trading volume of 1,539,240 shares, compared to its average volume of 2,664,851. Becton, Dickinson and Company has a one year low of $162.29 and a one year high of $251.99. The firm has a market capitalization of $54.38 billion, a P/E ratio of 13.30, a price-to-earnings-growth ratio of 1.77 and a beta of 0.25. The stock has a fifty day moving average of $187.60 and a two-hundred day moving average of $183.36. The company has a current ratio of 1.11, a quick ratio of 0.64 and a debt-to-equity ratio of 0.69.

Healthcare Stocks With at Least 30 Years of Dividend Increases

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%.The business had revenue of $5.32 billion for the quarter. Research analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 31st. Stockholders of record on Monday, December 8th will be given a $1.05 dividend. The ex-dividend date of this dividend is Monday, December 8th. This is a boost from Becton, Dickinson and Company's previous quarterly dividend of $1.04. This represents a $4.20 annualized dividend and a dividend yield of 2.2%. Becton, Dickinson and Company's payout ratio is currently 71.36%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in BDX. Saudi Central Bank bought a new stake in shares of Becton, Dickinson and Company in the first quarter valued at approximately $26,000. Activest Wealth Management increased its stake in Becton, Dickinson and Company by 285.3% during the 3rd quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier's stock worth $25,000 after acquiring an additional 97 shares during the period. Imprint Wealth LLC acquired a new position in Becton, Dickinson and Company in the 3rd quarter valued at $25,000. SOA Wealth Advisors LLC. lifted its position in shares of Becton, Dickinson and Company by 256.8% during the 3rd quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier's stock valued at $25,000 after acquiring an additional 95 shares during the period. Finally, Kelly Lawrence W & Associates Inc. CA acquired a new stake in shares of Becton, Dickinson and Company during the 1st quarter worth $31,000. Institutional investors and hedge funds own 86.97% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on BDX shares. Piper Sandler cut their target price on shares of Becton, Dickinson and Company from $200.00 to $190.00 and set a "neutral" rating for the company in a research note on Friday, November 7th. Morgan Stanley raised their price objective on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the stock an "overweight" rating in a research report on Tuesday. Wells Fargo & Company boosted their price objective on Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an "equal weight" rating in a report on Friday, August 8th. Wall Street Zen downgraded Becton, Dickinson and Company from a "buy" rating to a "hold" rating in a research report on Saturday, November 8th. Finally, Royal Bank Of Canada dropped their price target on Becton, Dickinson and Company from $211.00 to $202.00 and set a "sector perform" rating for the company in a report on Friday, November 7th. Three equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, Becton, Dickinson and Company currently has an average rating of "Hold" and a consensus target price of $204.45.

Read Our Latest Stock Report on Becton, Dickinson and Company

Becton, Dickinson and Company Company Profile

(Get Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Should You Invest $1,000 in Becton, Dickinson and Company Right Now?

Before you consider Becton, Dickinson and Company, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.

While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here